Results 11 to 20 of about 20,878 (216)

Matching‐adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed‐duration venetoclax and ibrutinib in patients with treatment‐naïve chronic lymphocytic leukaemia [PDF]

British Journal of Haematology, EarlyView.
Talha Munir, Leyla Mohseninejad, P. Rakonczai, Balázs Dobi, Sheng Xu, Keri Yang, Remus Vezan, Nicolás Martinez Calle   +7 more
openalex   +2 more sources

Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice

Journal of Neuroinflammation, 2018
Background The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling.
Hye Yeon Nam, Jin Han Nam, Gwangho Yoon, Ju-Young Lee, Youngpyo Nam, Hye-Jin Kang, Hyun-Ji Cho, Jeongyeon Kim, Hyang-Sook Hoe   +8 more
doaj   +1 more source

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Haematologica, 2017
The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been reported in 6–16% of ibrutinib patients.
Jennifer R. Brown, Javid Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutre, Marie-Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger   +26 more
doaj   +1 more source

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Advances in Hematology, 2022
Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation.
Januario E. Castro, Paula A. Lengerke-Diaz, Juliana Velez Lujan, Michael Y. Choi, Eider F. Moreno-Cortes, Jose V. Forero, Juan Esteban Garcia-Robledo, Chaja Jacobs, Colin McCarthy, Alaina Heinen, Carlos I. Amaya-Chanaga, Thomas J. Kipps   +11 more
doaj   +1 more source

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells [PDF]

Brazilian Journal of Medical and Biological Research
Despite the widespread use of R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL), the therapeutic efficacy for this disease remains suboptimal, primarily due to the heterogeneity of refractory and/or relapsed diseases.
Fengbo Jin, Limei He, Yingying Chen, Wanlu Tian, Lixia Liu, Ling Ge, Wei Qian, Leiming Xia, Mingzhen Yang   +8 more
doaj   +1 more source

RETRACTED ARTICLE: Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway

Cell Death and Disease, 2023
Ibrutinib is a drug that inhibits the protein Burton’s tyrosine kinase and thereby the nuclear translocation of Nrf2, which played a key role in mediating the activation of antioxidants during stress conditions and ferroptosis resistance.
Jin-Feng Zhu, Yi Liu, Wen-Ting Li, Ming-Hui Li, Chao-Hui Zhen, Pei-Wei Sun, Ji-Xin Chen, Wen-Hao Wu, Wei Zeng   +8 more
doaj   +1 more source

Optimizing Ibrutinib Posology in Chronic Lymphocytic Leukemia Using a Semi-Mechanistic Pharmacometric Framework. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Ibrutinib, a Bruton's tyrosine kinase (Btk) inhibitor, is a key therapy for chronic lymphocytic leukemia (CLL). In clinical practice, adverse events, such as hypertension, frequently necessitate dose reductions or treatment discontinuation. Emerging evidence suggests that reduced doses may retain clinical efficacy while mitigating toxicity ...
Ibrahim EIK, Friberg LE.
europepmc   +2 more sources

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

Pharmaceutics, 2022
BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown.
Jia Liu, Zhuojun Liu, Jing Zhang, Xiaofang Chen, Junge Chen, Linlin Sui, Jian Yu   +6 more
doaj   +1 more source

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

eJHaem, 2021
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi, Mohammad‐Ali Okhovat, Layung Sekar Sih Wikanthi, Ann Svensson, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat‐Farsangi   +9 more
doaj   +1 more source

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Journal for ImmunoTherapy of Cancer, 2023
Background In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy.
Li Zhang, Matthew Crocker, Lawrence Fong, Lisa M Coussens, Charles D Lopez, Shamilene Sivagnanam, Meenal Sinha, Brandon Chen, Jaqueline Marquez, Alexander Cheung, Whitney Tamaki, Jacob Stultz, Kendra Todd, Courtney Betts, Madeline J Griffith, Isabelle Solman, Eric Liu, Denise Pener, Anne Fahlman, Erin Taber, Kimberly Lerner, Brindha Rajagopalan, Clarisha Ware, Mark Bridge, Johnson Vo, Hannah Dragomanovich, Julie Sudduth-Klinger, Gina Vaccaro, Margaret Tempero   +28 more
doaj   +1 more source